Sotyktu (deucravacitinib) / BMS - LARVOL DELTA

Case Report: Advanced IgA nephropathy with psoriasis and a complex clinicopathologic course. (PubMed, Front Nephrol) - "Targeted-release budesonide and deucravacitinib were started together. This case is best interpreted as a clinicopathologic observation rather than proof of drug efficacy. Biopsy-defined activity and chronicity helped explain the discordant changes in proteinuria and kidney function, while the longitudinal course generated a testable but unproven hypothesis of a possible inflammatory connection between psoriasis and IgA nephropathy."

Journal • Dermatology • Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Nephrology • Psoriasis • Renal Disease

Identification of Protein Signatures of Sjögren's Disease Activity and Their Modulation by Deucravacitinib in Anti-SSA Positive Patients with SLE: Results from a Phase 2 Study (ACR Convergence 2026) - No abstract available

Clinical • P2 data • Inflammatory Arthritis • Sjogren's Syndrome

Impact of Deucravacitinib Treatment on Cardiovascular Risk-Associated Scores and Biomarkers in Patients With Active Psoriatic Arthritis Results From Phase 3 Studies (ACR Convergence 2026) - No abstract available

Biomarker • Clinical • P3 data • Cardiovascular • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Phase 3 Trials for PsA: Achievement of Minimal Disease Activity, Individual Components, and Very Low Disease Activity Through Week 52 (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Ankylosing Spondylitis • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatology • Spondylarthritis • TYK2

Clinical Outcomes at Week 52 in Male and Female Patients With PsA Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies (ACR Convergence 2026) - No abstract available

Clinical data • P3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatology • Spondylarthritis

Long-term Multidomain Clinical Response to Deucravacitinib in SLE: Four-Year Integrated Analyses From a Phase 2 Randomized Study and Its Long-Term Extension (ACR Convergence 2026) - No abstract available

Clinical • P2 data • Inflammatory Arthritis

Identification of Proteomic Signatures Associated With Global and Domain Specific Disease Activity in SLE and Their Modulation by Deucravacitinib in a Phase 2 Study (ACR Convergence 2026) - No abstract available

Clinical • P2 data • Inflammatory Arthritis

Comparative Efficacy and Safety of Upadacitinib Versus Deucravacitinib in Biologic-Naïve Patients with Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Improvement in the Axial Domain With Deucravacitinib Through Week 52 in Patients With PsA and Axial Involvement: 2 Randomized, Controlled Phase 3 Trials (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Ankylosing Spondylitis • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatology • Spondylarthritis

Impact of Deucravacitinib, a Tyk2 Inhibitor, on Epithelial Cells Function in Sjögren's Disease in a Salivary Gland Organoid Models (ACR Convergence 2026) - No abstract available

Sjogren's Syndrome • TYK2

Identification of Protein Signatures Tracking Changes of Disease Activity of PsA Disease Domains and Improvement With Deucravacitinib Treatment in Phase 3 Clinical Studies (ACR Convergence 2026) - P3 | "We identified circulating protein signatures that track longitudinal changes in PsA DA and key clinical domains, reflecting core biological processes including systemic inflammation, innate/myeloid activation and recruitment, tissue injury, matrix remodeling, and counter‑regulatory responses. Modulation of these signatures distinguished responders from nonresponders; DEUC was associated with significant attenuation of these PsA‑relevant biological signals."

Clinical • P3 data • Ankylosing Spondylitis • Immunology • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • TYK2

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (clinicaltrials.gov) - P2 | N=7 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | N=30 ➔ 7 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Deucravacitinib in Hidradenitis Suppurativa: An Open Label Proof of Concept Study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Acne Vulgaris • Dermatology • Hidradenitis Suppurativa • Immunology

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years (Bristol-Myers Squibb Press Release) - "These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Huntington Beach, California...Among patients who entered the OLE, Sotyktu demonstrated durable efficacy, with clinical responses continuing to improve from Week 16 through Week 52 and maintained through Week 104. Responses were robust across key clinical efficacy measures, including American College of Rheumatology (ACR) 20/50/70 and Minimal Disease Activity (MDA), both for patients who received Sotyktu continuously from the start of the Phase 3 study through the OLE and patients who switched from placebo to Sotyktu at Week 16 and continued Sotyktu through the remainder of the Phase 3 study and OLE...Among patients who received Sotyktu continuously from the beginning of the Phase 3 study through the OLE, ACR 20/50/70 response rates at Week 104 were 76.2%, 52.6% and 34.6%, respectively, based on observed analysis, and 65.3%, 44.9% and 29.4%, respectively, using nonresponder imputation (NRI)."

P3 data • Immunology • Psoriatic Arthritis

Deucravacitinib-Induced Remission of Refractory Discoid Lupus Erythematosus and Plaque Psoriasis: A Clinical Case Supported by Reflectance Confocal Microscopy (EADV 2026) - No abstract available

Clinical • Dermatology • Discoid Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Plaque Psoriasis • Psoriasis

Deucravacitinib in highly pre-treated refractory lichen planopilaris (EADV 2026) - No abstract available

Lichen Planus

Real-world effectiveness and safety of deucravacitinib through 52 weeks of treatment for moderate to severe plaque psoriasis in Germany: results from the DELPHIN study (DELPHIN) (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Deucravacitinib: dual efficacy in alopecia areata and difficult-to-treat areas of psoriasis (EADV 2026) - No abstract available

Clinical • Alopecia • Dermatology • Immunology • Psoriasis

Real-world data assessing the efficacy and tolerability of deucravacitinib and apremilast: A retrospective, single-centre observational study (EADV 2026) - No abstract available

Observational data • Real-world • Real-world evidence • Retrospective data • Dermatology • Dermatopathology • Immunology • Psoriasis

Deucravacitinib in the treatment of genital psoriasis: real-world evidence from an italian multicentric study (EADV 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Eczematous component in psoriasis is possibly a negative prognostic factor for deucravacitinib treatment outcome (EADV 2026) - No abstract available

Biomarker • Clinical • Atopic Dermatitis • Dermatology • Immunology • Psoriasis

Efficacy and Acceptability of Deucravacitinib in Moderate-to-Severe Psoriasis with Comorbidities Resistant to Conventional Therapy: A Real-World Study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Effect of Risankizumab Compared With Deucravacitinib on Health-Related Quality of Life and Treatment Satisfaction Among Patients With Moderate Plaque Psoriasis: Results From the Phase 4 IMMpactful Trial (EADV 2026) - No abstract available

Clinical • HEOR • P4 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Risankizumab Versus Deucravacitinib in Adult Patients With Moderate Plaque Psoriasis: 52-Week Results From IMMpactful, a Phase 4 Multicenter, Randomized, Study (EADV 2026) - No abstract available

Clinical • P4 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Selective TYK2 Inhibition in Plaque Psoriasis: A Systematic Review of Deucravacitinib with Clinical Perspective (EADV 2026) - No abstract available

Clinical • Review • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • TYK2